Pharmacokinetics of PEGylated recombinant human endostatin (M 2 ES) in rats
Zuo-gang Li,Lin Jia,Li-fang Guo,Min Yu,Xu Sun,Wen Nie,Yan Fu,Chun-ming Rao,Jun-zhi Wang,Yong-zhang Luo
DOI: https://doi.org/10.1038/aps.2015.16
IF: 7.169
2015-01-01
Acta Pharmacologica Sinica
Abstract:Aim: M 2 ES is PEGylated recombinant human endostatin. In this study we investigated the pharmacokinetics, tissue distribution, and excretion of M 2 ES in rats. Methods: 125 I-radiolabeled M 2 ES was administered to rats by intravenous bolus injection at 3 mg/kg. The pharmacokinetics, tissue distribution and excretion of M 2 ES were investigated using the trichloroacetic acid (TCA) precipitation method. Results: The serum M 2 ES concentration-time curve after a single intravenous dose of 3 mg/kg in rats was fitted with a non-compartment model. The pharmacokinetic parameters were evaluated as follows: C max =28.3 μg·equ/mL, t 1/2 =71.5 h, AUC (0–∞) =174.6 μg·equ·h/mL, Cl=17.2 mL·h −1 ·kg −1 , MRT=57.6 h, and V ss =989.8 mL/kg for the total radioactivity; C max =30.3 μg·equ/mL, t 1/2 =60.1 h, AUC (0–∞) =146.2 μg·equ·h/mL, Cl=20.6 mL·h −1 ·kg −1 , MRT=47.4 h, and V ss =974.6 mL/kg for the TCA precipitate radioactivity. M 2 ES was rapidly and widely distributed in various tissues and showed substantial deposition in kidney, adrenal gland, lung, spleen, bladder and liver. The radioactivity recovered in the urine and feces by 432 h post-dose was 71.3% and 8.3%, respectively. Only 0.98% of radioactivity was excreted in the bile by 24 h post-dose. Conclusion: PEG modification substantially prolongs the circulation time of recombinant human endostatin and effectively improves its pharmacokinetic behavior. M 2 ES is extensively distributed in most tissues of rats, including kidney, adrenal gland, lung, spleen, bladder and liver. Urinary excretion was the major elimination route for M 2 ES.